Mablink Bioscience is a company based in Lyon (France), founded in 2018, operating in the field of immuno-oncology.
The company is developing an innovative chemical masking platform for the optimization of antibody conjugate drug candidates (ADCs) for the treatment of cancer.
The project is part of an innovation process aimed at bringing to market a new generation of ADCs, more effective and better tolerated by the body, to fight various types of cancer.
Financing round - Series A
Diagnostic & Therapeutic Platforms
Number of Employees